Skip to Content

Danaher Corp - Stock Quote DHR

Rating as of

Morningstar's Danaher Corp Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Danaher Benefits From Omicron Variant Surge in Q1, but Headwinds Emerging; Shares Rich

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Danaher turned in strong operating results for the first quarter, which included the omicron variant surge that helped the firm exceed our expectations and FactSet consensus. However, Danaher maintained its guidance for the year, which suggests growth will decelerate significantly, and we are maintaining our $200 fair value estimate. Shares still appear rich to us when considering the potential for a profit growth reset, as the COVID-19 pandemic likely turns endemic in the near future.

Read Full Analysis

Danaher Corp's Company Profile

Business Description

In 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.

2200 Pennsylvania Avenue, North West, Suite 800W
Washington, DC, 20037-1701
T +1 202 828-0850
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 80,000

Danaher Corp's Related Articles & News